Last reviewed · How we verify
Intravenous (IV) zanamivir
Intravenous (IV) zanamivir is a Neuraminidase inhibitor Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Severe influenza infection in hospitalized patients, Influenza A and B infection.
Zanamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells by inhibiting the viral neuraminidase enzyme.
Zanamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells by inhibiting the viral neuraminidase enzyme. Used for Severe influenza infection in hospitalized patients, Influenza A and B infection.
At a glance
| Generic name | Intravenous (IV) zanamivir |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza virus neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Zanamivir binds to and inhibits influenza virus neuraminidase, a surface enzyme responsible for cleaving sialic acid receptors on host cells. This prevents the release of newly formed viral particles from infected cells, thereby reducing viral spread and limiting infection progression. The IV formulation allows for systemic delivery in hospitalized patients with severe influenza.
Approved indications
- Severe influenza infection in hospitalized patients
- Influenza A and B infection
Common side effects
- Bronchospasm
- Nausea
- Vomiting
- Diarrhea
- Headache
Key clinical trials
- An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection (PHASE2)
- A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (PHASE3)
- A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection (PHASE3)
- A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers (PHASE1)
- Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults (PHASE1)
- Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital (PHASE2)
- A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous (IV) zanamivir CI brief — competitive landscape report
- Intravenous (IV) zanamivir updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Intravenous (IV) zanamivir
What is Intravenous (IV) zanamivir?
How does Intravenous (IV) zanamivir work?
What is Intravenous (IV) zanamivir used for?
Who makes Intravenous (IV) zanamivir?
What drug class is Intravenous (IV) zanamivir in?
What development phase is Intravenous (IV) zanamivir in?
What are the side effects of Intravenous (IV) zanamivir?
What does Intravenous (IV) zanamivir target?
Related
- Drug class: All Neuraminidase inhibitor drugs
- Target: All drugs targeting Influenza virus neuraminidase
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Severe influenza infection in hospitalized patients
- Indication: Drugs for Influenza A and B infection
- Compare: Intravenous (IV) zanamivir vs similar drugs
- Pricing: Intravenous (IV) zanamivir cost, discount & access